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Letters e147Complete prednisone taper was accomplished
after famciclovir 500 mg was given 3 times daily.1
The patient remains clear at 19 months on oral
famciclovir 500 mg daily.
Patient 2 is a 65-year-old Caucasian woman who
was seen 1 year earlier by a dermatologist for
erythematous targetoid lesions on her right lower
extremity, which was treated with doxycycline
100 mg twice daily for 2 weeks without effect.
Lyme titer was negative. She presented in July 2013
with an erythematous targetoid macule of her
left calf with a central bulla of 5 days’ duration.
Biopsy showed erythema multiforme. Five weeks
of valacyclovir 1 g daily and desoximetasone
0.25% ointment twice daily failed. Confirmatory
HSV 1 and 2 and M. pneumoniae titers were
positive. Since switching to famciclovir 500 mg
daily, the patient has been free of HAEM lesions
for 7 months.
Patient 3 is a 27-year-old Latina woman with
serologically proven HSV 1 and 2 who presented
several years ago to a dermatologist with targetoid
macules and bullae of her hands and elbows
and erosions of her hard palate. After valacyclovir
treatment failed, she saw a rheumatologist, who
diagnosed pemphigus vulgaris, reportedly by biopsy
(no anti-desmoglein titers were drawn), and initiated
prednisone at varying doses as high as 80 mg, a
regimen she has been on since. Her course waxed
and waned, prompting a trial of IVIg and rituximab,
which resulted in 5 months of improvement.
Ultimately, her lesions recurred. On presentation to
us in February 2014, she was Cushingoid with
erythematous targetoid lesions with central bullae
on her fingers and erosions on her hard palate.
Biopsy and positive titers of HSV 1 and 2 confirmed
HAEM. Bone densitometry predictably revealed
osteopenia. Following treatment with famciclovir
500 mg orally twice daily, her palatal and cutaneous
erosions resolved completely. Upon prednisone
taper, some lesions recurred, prompting increase of
famciclovir to 3 times daily. At 75 days since
beginning treatment, she is stable on this dose and
off prednisone.
Our patients failed valacyclovir, then multiple
immunosuppressive medications, yet responded
dramatically to famciclovir. Patients 1 and 3 suffered
significant morbidity from long-term corticosteroid
therapy and were exposed fruitlessly to numerous
immunosuppressive medications. We have found
famciclovir 500 mg orally 2 to 3 times daily to be
effective initial treatment for refractory cases of
HAEM with maintenance therapy at 500 mg daily. A
failed trial of valacyclovir should not preclude a trial
of famciclovir. All safe antiviral medications should
Open access under CC BY-NC-ND license.be trialed in cases of chronic HAEM before moving to
long-term immunosuppressive therapy.
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Acute generalized exanthematous pustulosis
associated with 2 common medications:
Hydroxyzine and benzocaine
To the Editor: Acute generalized exanthematous
pustulosis (AGEP) is a significant adverse cutaneous
reaction most often induced by drugs or acute
infections. In drug-induced AGEP, determining the
responsible medication is important, as is identifying
cross-reactants, in that early discontinuation and
future avoidance of these agents help reduce
morbidity.
The clinical hallmark of AGEP is the sudden onset
of multiple, disseminated, nonfollicular, sterile pus-
tules on an erythematous background, usually with
intertriginous accentuation associated with fever
(temperature greater than 388C) and neutrophilia
([73 109⁄ L). AGEP generally resolves 2 weeks after
the causative drug is withdrawn.
In our first case, AGEP induced by benzocaine,
a 67-year-old man presented with a severe, wide-
spread, pustular eruption with associated fevers,
rigors, watery diarrhea, and malaise. Twenty-four
hours before the drug eruption, the patient had
dental extraction and received a benzocaine spray.
Examination demonstrated confluent erythema
studded with nonfollicular pustules distributed on
the face, trunk, and extremities. Biopsies demon-
strated histologic features consistent with AGEP.
The patient was treated with oral prednisone and
topical corticosteroids. After a 3-day hospitalization,
he clinically improved and was discharged home.
Fig 1. General guidelines for patch testing for a suspected drug eruption ( for the general
dermatologist).4,5
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had a 31 pustular reaction to benzocaine at 96 hours.
A biopsy of the benzocaine patch test site was
consistent with allergic contact dermatitis.
Inour secondcase, AGEPcausedbyhydroxyzine, a
48-year-old woman with a history of psoriasis
presented to a walk-in clinic complaining of
generalized pruritus. She was prescribed oral
hydroxyzine. Twenty-four hours after hydroxyzine
ingestion, a burning erythematous eruption deve-
loped on her trunk, extremities, and genitalia. She
discontinued the hydroxyzine on day 4. Two days
after discontinuing hydroxyzine, fever developed and
skin eruption worsened. Skin examination revealed
widespread small nonfollicular pustules on an
erythematous background. Biopsies showed features
of AGEP.The patient was treated with prednisone and
betamethasone valerate 0.1% ointment. She was
later tested in the Patch Test Clinic and a 3111
local reaction developed in response to 10%
hydroxyzine at 48 and 120 hours. Biopsy of the test
site showed a neutrophilic dermatosis favoring
AGEP.
In each of the aforementioned cases, the eruption
started approximately 24 hours after the drug
exposure. Each patient remembered at least 1 past
exposure to the responsible medication.
The sensitivity of patch testing to drugs in AGEP is
up to 80%.1 Patch testingwith the suspected drug can
mimic AGEP clinically at the patch test site where it
can be biopsied to confirm the diagnosis. The biopsy
of the patch site could show classic AGEP or allergic
contact dermatitis as in the cases described.
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to use for patch testing (Fig 1).
To the best of our knowledge, there are no
reported cases of AGEP secondary to benzocaine
and only 2 previous reports of AGEP caused by
hydroxyzine.2,3 It may be that these common
medications have caused AGEP in the past that was
either unrecognized or not reported. Regardless,
it is important that dermatologists be aware of this
uncommon yet important adverse event.
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infliximab treatment in a patient with
psoriasis: Use of cyclosporine as a rescue
therapy
To the Editor:Cutaneous CD81 pseudolymphoma has
been reported in HIV-infected patients in association
with a reactive cutaneous infiltration of HIV-specific
CD81 cytotoxic T cells.1 The diagnostic features
include extensive plaquesor erythrodermamimicking
mycosis fungoides or Sezary syndrome, eosinophilia,
and a dermal CD81 cytotoxic T-lymphocyte infiltrate
without T-cell receptor rearrangement.2,3 Herein,
we describe an HIV-negative patient with psoriasisin whom erythrodermic CD81 pseudolymphoma
developed after treatment with infliximab.
A 32-year-old white woman had a 3-year history
of biopsy-proven severe pustular psoriasis that
was unresponsive to topical corticosteroids and
narrowband ultraviolet B phototherapy. After
screening for infection, neoplasm, and autoimmu-
nity, all of which were negative, the patient was
given infliximab at a dose of 5 mg/kg at weeks 0, 2,
and 6, and then every 2 months. Her psoriasis
improved and at least a 50% reduction in body
surface area compared to baseline was observed
after 12 weeks. Eleven months later, severe
pruritic erythroderma associated with palmoplantar
hyperkeratosis and generalized lymphadenopathy
developed. Serologic and/or serum DNA detection
studies for Bartonella henselae, cytomegalovirus,
Epstein-Barr virus, HIV, and Toxoplasma gondii
were negative.
Two lesional skin biopsies showed a papillary
dermal lymphocytic infiltrate composed of small-
and medium-sized cells with mild epidermotropism.
Immunohistochemistry showed an overwhelming
predominance of CD21, CD31, CD51, CD71, and
CD81 T cells in the infiltrate. Scattered eosinophils
were also observed. Immunostaining of CD8 T cells
showed TiA-1 and granzyme B expression,
indicating their cytotoxic lineage. Clonal T-cell
receptor and immunoglobulin heavy chain gene
rearrangements were not detected. Direct immuno-
fluorescence was negative. Immunophenotyping
performed on lymph node and bone marrow biopsy
specimens showed a polyclonal CD8 T-cell infiltrate.
A blood cell count showed 1992 CD41 T cells/mm3,
3916 CD81 T cells/mm3, and 1160 eosinophils/mm3.
The CD4/CD8 ratio was 0.51, and there were no
circulating Sezary cells.
A diagnosis of erythrodermic CD81 pseudolym-
phoma was made, and infliximab was discontinued.
Despite infliximab withdrawal, the erythroderma
persisted, and the use of topical and systemic
corticosteroids followed by methotrexate was
unsuccessful (Fig 1). Because of worsening skin
symptoms associated with edema, chills, and overall
deterioration in the patient’s condition, treatment
with cyclosporine at doses up to 5 mg/kg/day was
initiated. The patient’s condition dramatically
improved and she was in complete clinical remission
within 4 months (Fig 2). The CD4/CD8 ratio
improved to 0.85.
As far as we know, in addition to our case, there
have been only 2 other reported cases of cutaneous
pseudolymphoma associated with anti-tumor
necrosis factor (TNF) therapy. One was induced by
adalimumab and subsequently the same eruption
